|
1
|
Li W, Xu Y, Zeng X, Tan J, Wang Y, Wu H,
Li M and Yi C: Etiological relationship between lipid metabolism
and endometrial carcinoma. Lipids Health Dis. 22:1162023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kokts-Porietis RL, Elmrayed S, Brenner DR
and Friedenreich CM: Obesity and mortality among endometrial cancer
survivors: A systematic review and meta-analysis. Obes Rev.
22:e133372021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang X, Glubb DM and O'Mara TA: Dietary
factors and endometrial cancer risk: A mendelian randomization
study. Nutrients. 15:6032023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Makker V, MacKay H, Ray-Coquard I, Levine
DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis
Primers. 7:882021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sheikh MA, Althouse AD, Freese KE, Soisson
S, Edwards RP, Welburn S, Sukumvanich P, Comerci J, Kelley J,
LaPorte RE and Linkov F: USA endometrial cancer projections to
2030: Should we be concerned? Future Oncol. 10:2561–2568. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Wijk F, Huikeshoven F, Abdulkadir L,
Ewing P and Burger C: Stage III and IV endometrial cancer: A
20-year review of patients. Int J Gynecol Cancer. 16:1648–1655.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vermij L, Jobsen JJ, León-Castillo A,
Brinkhuis M, Roothaan S, Powell ME, de Boer SM, Khaw P, Mileshkin
LR, Fyles A, et al: Prognostic refinement of NSMP high-risk
endometrial cancers using oestrogen receptor immunohistochemistry.
Br J Cancer. 128:1360–1368. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crosbie EJ, Kitson SJ, McAlpine JN,
Mukhopadhyay A, Powell ME and Singh N: Endometrial cancer. Lancet.
399:1412–1428. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tian Y and Luo H: Diagnostic accuracy of
transvaginal ultrasound examination for local staging of cervical
cancer: A systematic review and meta-analysis. Med Ultrason.
24:348–355. 2022.PubMed/NCBI
|
|
10
|
Elmstrøm-Christensen LB and Lauszus FF:
Diagnostic delay of gynaecological cancer in women with
postmenopausal bleeding. Dan Med J. 69:A092107442022.PubMed/NCBI
|
|
11
|
Oaknin A, Bosse TJ, Creutzberg CL,
Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza
MR, et al: Endometrial cancer: ESMO clinical practice guideline for
diagnosis, treatment and follow-up. Ann Oncol. 33:860–877. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tronconi F, Nero C, Giudice E, Salutari V,
Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F,
et al: Advanced and recurrent endometrial cancer: State of the art
and future perspectives. Crit Rev Oncol Hematol. 180:1038512022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vermij L, Smit V, Nout R and Bosse T:
Incorporation of molecular characteristics into endometrial cancer
management. Histopathology. 76:52–63. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kasius JC, Pijnenborg JMA, Lindemann K,
Forsse D, van Zwol J, Kristensen GB, Krakstad C, Werner HMJ and
Amant F: Risk stratification of endometrial cancer patients: FIGO
stage, biomarkers and molecular classification. Cancers (Basel).
13:58482021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kiss I, Kolostova K, Pawlak I and Bobek V:
Circulating tumor cells in gynaecological malignancies. J BUON.
25:40–50. 2020.PubMed/NCBI
|
|
16
|
Hu X, Zang X and Lv Y: Detection of
circulating tumor cells: Advances and critical concerns. Oncol
Lett. 21:4222021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Castro-Giner F and Aceto N: Tracking
cancer progression: From circulating tumor cells to metastasis.
Genome Med. 12:312020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Law KS, Huang CE and Chen SW: Detection of
circulating tumor cell-related markers in gynecologic cancer using
microfluidic devices: A pilot study. Int J Mol Sci. 24:23002023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin W, Zhou Q, Wang CQ, Zhu L, Bi C, Zhang
S, Wang X and Jin H: LncRNAs regulate metabolism in cancer. Int J
Biol Sci. 16:1194–1206. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park EG, Pyo SJ, Cui Y, Yoon SH and Nam
JW: Tumor immune microenvironment lncRNAs. Brief Bioinform.
23:bbab5042022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju
HQ: LncRNA-mediated posttranslational modifications and
reprogramming of energy metabolism in cancer. Cancer Commun (Lond).
41:109–120. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xing C, Sun SG, Yue ZQ and Bai F: Role of
lncRNA LUCAT1 in cancer. Biomed Pharmacother. 134:1111582021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang G, Sun J and Zhang X: A novel
cuproptosis-related LncRNA signature to predict prognosis in
hepatocellular carcinoma. Sci Rep. 12:113252022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding H, Jiang F, Deng L, Wang J, Wang P,
Ji M, Li J, Shi W, Pei Y, Li J, et al: Prediction of clinical
outcome in endometrial carcinoma based on a 3-lncRNA signature.
Front Cell Dev Biol. 9:8144562021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xin W, Gao X, Zhao S, Zhao P, Yu H, Wu Q
and Hua K: LncRNA RP11-395G23.3 suppresses the endometrial cancer
progression via regulating microRNA-205-5p/PTEN axis. Am J Transl
Res. 12:4422–4433. 2020.PubMed/NCBI
|
|
26
|
Esteller M: Aberrant DNA methylation as a
cancer-inducing mechanism. Annu Rev Pharmacol Toxicol. 45:629–656.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishiyama A and Nakanishi M: Navigating
the DNA methylation landscape of cancer. Trends Genet.
37:1012–1027. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Q, Xiong F, Wu G, Liu W, Chen J, Wang
B and Chen Y: Gene body methylation in cancer: Molecular mechanisms
and clinical applications. Clin Epigenetics. 14:1542022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Papanicolau-Sengos A and Aldape K: DNA
methylation profiling: An emerging paradigm for cancer diagnosis.
Annu Rev Pathol. 17:295–321. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jamshidi A, Liu MC, Klein EA, Venn O,
Hubbell E, Beausang JF, Gross S, Melton C, Fields AP, Liu Q, et al:
Evaluation of cell-free DNA approaches for multi-cancer early
detection. Cancer Cell. 40:1537–1549.e12. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Caplakova V, Babusikova E, Blahovcova E,
Balharek T, Zelieskova M and Hatok J: DNA methylation machinery in
the endometrium and endometrial cancer. Anticancer Res.
36:4407–4420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qi B, Sun Y, Lv Y, Hu P, Ma Y, Gao W, Li
S, Zhang X, Jin X, Liou Y, et al: Hypermethylated CDO1 and CELF4 in
cytological specimens as triage strategy biomarkers in endometrial
malignant lesions. Front Oncol. 13:12893662023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Dong L, Xu J, Guo L, Wang Y, Wan
K, Jing W, Zhao L, Feng X, Zhang K, et al: Hypermethylated CDO1 and
ZNF454 in cytological specimens as screening biomarkers for
endometrial cancer. Front Oncol. 12:7146632022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lawrence R, Watters M, Davies CR, Pantel K
and Lu YJ: Circulating tumour cells for early detection of
clinically relevant cancer. Nat Rev Clin Oncol. 20:487–500. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao H, Wen L, Li Z and Xia C: Analysis of
diagnostic value of CTC and CTDNA in early lung cancer. Cell Mol
Biol (Noisy-le-grand). 69:57–62. 2023. View Article : Google Scholar
|
|
37
|
Francini S, Duraes M, Rathat G, Macioce V,
Mollevi C, Pages L, Ferrer C, Cayrefourcq L and Alix-Panabières C:
Circulating tumor cell detection by liquid biopsy during
early-stage endometrial cancer surgery: A pilot study.
Biomolecules. 13:4282023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Y, Fan Z, Meng Y, Liu S and Zhan H:
Blood-based DNA methylation signatures in cancer: A systematic
review. Biochim Biophys Acta Mol Basis Dis. 1869:1665832023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Harada H, Hosoda K, Moriya H, Mieno H, Ema
A, Ushiku H, Washio M, Nishizawa N, Ishii S, Yokota K, et al:
Cancer-specific promoter DNA methylation of cysteine dioxygenase
type 1 (CDO1) gene as an important prognostic biomarker of gastric
cancer. PLoS One. 14:e02148722019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kong LH, Xiao XP, Wan R, Chao XP, Chen XJ,
Wang J, Wu HW and Li L: The role of DNA methylation in the
screening of endometrial cancer in postmenopausal women. Zhonghua
Yi Xue Za Zhi. 103:907–912. 2023.(In Chinese). PubMed/NCBI
|
|
41
|
Huang RL, Su PH, Liao YP, Wu TI, Hsu YT,
Lin WY, Wang HC, Weng YC, Ou YC, Huang TH and Lai HC: Integrated
epigenomics analysis reveals a DNA methylation panel for
endometrial cancer detection using cervical scrapings. Clin Cancer
Res. 23:263–272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Krasnyi AM, Gadzhieva LT, Kokoeva DN,
Kosenko MG, Yarotskaya EL, Pavlovich SV, Ashrafyan LA and Sukhikh
GT: Analysis of CDO1, PITX2, and CDH13 gene methylation in early
endometrial cancer for prediction of medical treatment outcomes.
Int J Mol Sci. 25:48922024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Salem ME, Bodor JN, Puccini A, Xiu J,
Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES,
et al: Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific
alterations and tumor mutational burden in 1057 microsatellite
instability-high solid tumors. Int J Cancer. 147:2948–2956. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kawaguchi M, Banno K, Yanokura M,
Kobayashi Y, Kishimi A, Ogawa S, Kisu I, Nomura H, Hirasawa A,
Susumu N and Aoki D: Analysis of candidate target genes for
mononucleotide repeat mutation in microsatellite instability-high
(MSI-H) endometrial cancer. Int J Oncol. 35:977–982.
2009.PubMed/NCBI
|
|
45
|
Vasseur A, Kiavue N, Bidard FC, Pierga JY
and Cabel L: Clinical utility of circulating tumor cells: An
update. Mol Oncol. 15:1647–1666. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Magbanua MJM, Hendrix LH, Hyslop T, Barry
WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga
JY, et al: Serial analysis of circulating tumor cells in metastatic
breast cancer receiving first-line chemotherapy. J Natl Cancer
Inst. 113:443–452. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Krebs MG, Sloane R, Priest L, Lancashire
L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G,
et al: Evaluation and prognostic significance of circulating tumor
cells in patients with non-small-cell lung cancer. J Clin Oncol.
29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen J, Xie T, Yang J, Lin X, Huang L, Su
S and Deng J: Feasibility study of expressing epcam +/vimentin +
CTC in prostate cancer diagnosis. J Cancer Res Clin Oncol.
149:8699–8709. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rahmati M and Chen X: Separation of
circulating tumor cells from blood using dielectrophoretic DLD
manipulation. Biomed Microdevices. 23:492021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Di Trapani M, Manaresi N and Medoro G:
DEPArray™ system: An automatic image-based sorter for
isolation of pure circulating tumor cells. Cytometry A.
93:1260–1266. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wei X, Chen K, Guo S, Liu W and Zhao XZ:
Emerging microfluidic technologies for the detection of circulating
tumor cells and fetal nucleated red blood cells. ACS Appl Bio
Mater. 4:1140–1155. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
S Iliescu F, Sim WJ, Heidari H, P Poenar
D, Miao J, Taylor HK and Iliescu C: Highlighting the uniqueness in
dielectrophoretic enrichment of circulating tumor cells.
Electrophoresis. 40:1457–1477. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Burr R, Edd JF, Chirn B, Mishra A, Haber
DA, Toner M and Maheswaran S: Negative-selection enrichment of
circulating tumor cells from peripheral blood using the
microfluidic CTC-iChip. Methods Mol Biol. 2471:309–321. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Andree KC, van Dalum G and Terstappen LW:
Challenges in circulating tumor cell detection by the CellSearch
system. Mol Oncol. 10:395–407. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang J, Dallmann R, Lu R, Yan J and
Charmet J: Flow rate-independent multiscale liquid biopsy for
precision oncology. ACS Sens. 8:1200–1210. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chi Y, Wang D, Wang J, Yu W and Yang J:
Long non-coding RNA in the pathogenesis of cancers. Cells.
8:10152019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Paul Y, Thomas S, Patil V, Kumar N, Mondal
B, Hegde AS, Arivazhagan A, Santosh V, Mahalingam K and
Somasundaram K: Genetic landscape of long noncoding RNA (lncRNAs)
in glioblastoma: Identification of complex lncRNA regulatory
networks and clinically relevant lncRNAs in glioblastoma.
Oncotarget. 9:29548–29564. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang M, Chen Z, Zhang S, Wu L, Jie Y,
Liao Y, Huang Y, Chen J and Shi B: Analysis of differentially
expressed long non-coding RNAs and the associated TF-mRNA network
in tongue squamous cell carcinoma. Front Oncol. 10:14212020.
View Article : Google Scholar : PubMed/NCBI
|
